Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay
- Ability to sequence and surveil evolution of virus mutations over time and geography -
- Enables batch analysis of up to 96 samples at once; higher-plex assay development ongoing -
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005311/en/
The SARS-CoV-2 NGS Assay is an in vitro diagnostic test, a highly sensitive nucleic acid hybridization capture-based assay, intended for the detection of SARS-CoV-2 RNA.
The SARS-CoV-2 NGS Assay has the ability to analyze the entire RNA viral sequence, to determine the presence or absence of the virus. Furthermore, in an optional research-use only (RUO) report the software analyzes the RNA sequence to detect genetic variants and lineages of SARS-CoV-2.1 The hybridzation capture-based approach utilized in this assay maximizes the number of genetic variants identified, where other sequencing methods may miss mutations in certain regions.
New mutations in the SARS-CoV-2 virus continue to accumulate and circulate around the world, creating genetic variants of concern that may alter transmissability or vaccine efficacy, including the most recent B.1.1.7, B.1.351, and P.1 lineages initially found in the
According to the World Health Organization’s Genome Sequencing for SARS-CoV-2, published
“While there are many available high-throughput diagnostic tests available for COVID-19, our solution enables clinicians and researchers the ability to sequence and surveil the evolution of mutations in the virus over time and geography. This is especially significant at the moment as more variants are identified that are more contagious,” said Emily M. Leproust, Ph.D., CEO and co-founder of
The assay utilizes Twist Bioscience’s unique ability to rapidly develop virus-specific panels through DNA synthesis and Biotia’s comprehensive data analysis software and reporting capabilities. The SARS-CoV-2 NGS Assay was validated on a NextSeq® 550 Sequencing System. Because the assay analyzes the full sequence data, the test reduces the likelihood of a false-negative result. In contrast, a majority of SARS-CoV-2 tests based on polymerase chain reaction (PCR) only identify limited genetic markers of the virus.
In the separate and free RUO report, the full sequence of the virus is profiled, enabling improved understanding of mutations, genetic variability, and the evolution of the virus as it’s transmitted. A recent pre-print on MedRxiv and submitted for peer review details results of the NGS SARS-CoV-2 Assay with the COVID-DX Solution to detect the virus and its genetic variants.
"As SARS-CoV-2 continues to evolve, the need for insightful research tools leveraging NGS and evolutionary principles has become starkly clear,” commented Niamh O’Hara, Ph.D., CEO and co-founder of Biotia. “This assay also greatly expands testing options in the clinical space, bringing new technology to patients.”
“This test opens the door to a new diagnostic method and can also guide vaccine research, since it captures viral variants so well,” noted
About the Test and Interface
The SARS-CoV-2 NGS Assay is an in vitro diagnostic test intended for the qualitative identification of the SARS-CoV-2 virus from nasopharyngeal (NP), oropharyngeal (OP), anterior nasal and mid-turbinate nasal swabs, nasopharyngeal wash/aspirates, nasal wash/aspirates as well as from bronchoalveolar lavage (BAL) specimens from individuals suspected of having COVID-19 by their healthcare provider. The SARS-CoV-2 NGS Assay, which includes Twist Bioscience’s SARS-CoV-2 synthetic RNA controls, along with the Biotia COVID-DX software which generates a clinical report and RUO report, covers the entire virus genome and identifies all strains of SARS-CoV-2 in samples with as few as 800 viral copies per milliliter.
The complementary Biotia COVID-DX software provides a clinically-oriented report including the presence or absence of the SARS-CoV-2 virus. FASTQ files (sequencing output) can be generated in certified clinical laboratories and submitted to Biotia COVID-DX (v1.0), a cloud-based software, to generate clinical reports. Access to the Biotia COVID-DX software will be provided through a unique order number emailed to a clinician or researcher that includes credits for each kit purchased.
The SARS-CoV-2 NGS Assay and Biotia COVID-DX software are limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. The SARS-CoV-2 NGS Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the use of the Illumina NextSeq 500/550/550Dx Sequencing System, NGS workflows, and in vitro diagnostic procedures. The SARS-CoV-2 NGS Assay is only for use under the Food and Drug Administration’s Emergency Use Authorization. This test will become available for purchase in the coming weeks. For more information, click here.
Biotia is a health tech company located in
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the SARS-CoV-2 NGS Assay to successfully provide actionable information that can then be used to inform public health and clinical decisions, reduce the likelihood of a false positive or a false negative result, enable improved understanding of mutations, genetic variability, and the evolution of SARS-CoV-2 as it is transmitted and to advance COVID-19 research and control, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
1Variant detection and identification performance have not been evaluated by the FDA and these claims are not authorized under FDA’s Emergency Use Authorization.